Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells

Kiwon Ban, Seongho Bae, Youngsup Yoon

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

Original languageEnglish
Pages (from-to)2067-2077
Number of pages11
JournalTheranostics
Volume7
Issue number7
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Pluripotent Stem Cells
Cardiac Myocytes
Heart Diseases
Tissue Engineering
Cell- and Tissue-Based Therapy

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{1b51a73c819a471a8272d9617a048cc8,
title = "Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells",
abstract = "Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.",
author = "Kiwon Ban and Seongho Bae and Youngsup Yoon",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/thno.19427",
language = "English",
volume = "7",
pages = "2067--2077",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "7",

}

Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells. / Ban, Kiwon; Bae, Seongho; Yoon, Youngsup.

In: Theranostics, Vol. 7, No. 7, 01.01.2017, p. 2067-2077.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells

AU - Ban, Kiwon

AU - Bae, Seongho

AU - Yoon, Youngsup

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

AB - Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

UR - http://www.scopus.com/inward/record.url?scp=85019847084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019847084&partnerID=8YFLogxK

U2 - 10.7150/thno.19427

DO - 10.7150/thno.19427

M3 - Review article

VL - 7

SP - 2067

EP - 2077

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 7

ER -